Patent application number | Description | Published |
20130184681 | APPARATUS AND METHOD FOR NON-INTRAVENOUSLY ADMINISTERING A MEDICATION - A computer-based apparatus for dispensing a medication, including: at least one specially programmed computer; and a medication device. The at least one computer is arranged to automatically generate a medication regimen for a patient, the medication regimen including designation of a measure for an orally-administered or injectable medication; or automatically modify a medication regimen for a patient, by modifying a designation of a measure for an orally-administered or injectable medication. The medication device is arranged to: extract the orally-administered or injectable medication from a medication storage element; and non-intravenously dispense an amount of the orally-administered or injectable medication equal to the designated measure or the modified designated measure into a container. The at least one specially programmed computer is part of the medication device, is attached to the medication storage element, or is located remote from the medication device. | 07-18-2013 |
20130184682 | APPARATUS AND METHOD FOR NON-INTRAVENOUSLY ADMINISTERING A MEDICATION - A computer-based apparatus for dispensing a medication, including: at least one specially programmed computer; and, a medication device. The at least one specially programmed computer is arranged to calculate or modify, for a patient, a dosage for a first orally-administered or injectable medication and a constraint related to administration of the dosage by using a current point in time, a point in time at which a previous dosage of the first orally-administered or injectable medication was administered, information regarding a second medication prescribed for the patient, or real time physiological data for a patient. The medication device is arranged to: extract the first orally-administered or injectable medication from a medication storage element; and non-intravenously dispense the first orally-administered or injectable medication in accordance with the dosage and the constraint. | 07-18-2013 |
20130266358 | Media Feeding System for Cutting Dimensional Documents and Methods of Making and Using Same - A media feeding and cutting system is disclosed herein which comprises a media cutter including a cutting surface and a digital cutting device, a first feeder configured to automatically transport individual sheets of media from an in-feed receptacle toward the cutter, a positioner configured to position the medium on the cutting surface, a second feeder disposed adjacent to or connected to the cutting surface which is configured to automatically transport the cut medium from the cutter to an out-feed receptacle, and a processor configured to operate the cutter, first feeder, positioner and second feeder. Additional related systems and methods also are disclosed. | 10-10-2013 |
20140074980 | USB PORTABLE DOCUMENT SERVICES ENVIRONMENT - A method and system for providing a portable document services environment on a computer system is disclosed. An installation application may automatically be loaded from a portable device onto a computer system when the portable device is connected to the computer system. The computer system may automatically access a document service application on the portable device based on information contained in the installation application. One or more document service preferences may automatically be received from the portable device onto the computer system, and an electronic document may be selected. One or more document services may be performed for the selected electronic document based on the one or more document service preferences using the document service application. | 03-13-2014 |
20150290083 | APPARATUS AND METHOD FOR NON-INTRAVENOUSLY ADMINISTERING A MEDICATION - An apparatus for storing and dispensing a medication, including: a cartridge including a cavity for storing a first orally-administered or injectable medication for a patient; and a module, including a specially-programmed computer. The specially-programmed computer: attached to the cartridge, and arranged to: automatically generate or modify a medication regimen, including designation of a measure for the first orally-administered or injectable medication, for the patient by using information regarding a second medication, different from the first medication, prescribed for the patient, or real time physiological data for the patient; and transmit instructions to a medication device to extract the first orally-administered or injectable medication from the cartridge and non-intravenously dispense, into a container, an amount of the first orally-administered or injectable medication equal to the designated measure or the modified designated measure. | 10-15-2015 |
Patent application number | Description | Published |
20110119570 | AUTOMATED VARIABLE DIMENSION DIGITAL DOCUMENT ADVISOR - A system for creating variable dimension digital documents. The system includes a computer processor and a computer readable medium operably connected to the computer processor and having at least one software module installed on the computer readable medium and containing instructions for operating the computer processor to perform a process. The process includes the steps of receiving a user defined goal for creating a variable dimension digital document, wherein the user defined goal includes at least one recipient, determining at least one document template based upon the user defined goal, determining a plurality of digital assets to include in the variable dimension digital document based upon the document template and the user defined goal, creating a plurality of data files representing the potential variable dimension digital documents, and producing a results set including the potential variable dimension digital documents. | 05-19-2011 |
20110149337 | DIMENSIONAL DOCUMENT PRODUCTION METHOD AND SYSTEM - A method and system generate a workflow for the production of a three-dimensional document. A knowledge base contains production rules for several dimensional documents. The production rules relate to a plurality of jobs, i.e., units of work involved in the production of a dimensional document. The rules also identify human and/or mechanical resources required to complete each job. The system receives, from multiple service providers, capability information corresponding to each service provider's available resources. The capability information is associated with the production rules and stored in the knowledge base. When a user selects a dimensional document to be produced, the system selects appropriate production rules for the document, accesses the associated capability information, and automatically generates a workflow for the document. The system distributes various jobs in the workflow among at least two different service providers. | 06-23-2011 |
20150019301 | SYSTEM AND METHOD FOR CLOUD CAPABILITY ESTIMATION FOR USER APPLICATION IN BLACK-BOX ENVIRONMENTS USING BENCHMARK-BASED APPROXIMATION - A system and method for providing cloud performance capability estimation and supporting recommender systems by simulating bottleneck and its migration for any given complex application in a cost-efficient way are provided. To do this, first, the system and method builds an abstract performance model for an application based on the resource usage pattern of the application in an in-house test-bed (i.e., a white-box environment). Second, it computes relative performance scores of many different cloud configurations given from black-boxed clouds using a cloud metering system. Third, it applies the collected performance scores into the abstract performance model to estimate performance capabilities and potential bottleneck situations of those cloud configurations. Finally, using the model, it can support recommender systems by providing performance estimates and simulations of bottlenecks and bottleneck migrations between resource sub-systems while new resources are added or replaced. | 01-15-2015 |
Patent application number | Description | Published |
20110190207 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 08-04-2011 |
20120288886 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 11-15-2012 |
20130172275 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 07-04-2013 |
20130184211 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 07-18-2013 |
20130231277 | CHIMERIC FGF21 PROTEINS WITH ENHANCED BINDING AFFINITY FOR BETA-KLOTHO FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, AND RELATED METABOLIC DISORDERS - The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 09-05-2013 |
20130331316 | CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE - The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 12-12-2013 |
20130331317 | CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE - The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 12-12-2013 |
20130331325 | CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE - The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the αKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 12-12-2013 |
20140094406 | CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE - The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 04-03-2014 |
20140107022 | CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE - The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 04-17-2014 |
20140243260 | CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE - The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule. The present invention also relates to a pharmaceutical composition including an isolated chimeric protein and a pharmaceutically acceptable carrier. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule, and a pharmaceutically-acceptable carrier. Yet another aspect of the present invention relates to a method for treating a subject suffering from a disorder. This method includes selecting a subject suffering from the disorder and administering to the subject a therapeutically effective amount of a chimeric protein according to the present invention. | 08-28-2014 |